Protai Unveils Groundbreaking Discoveries in Biotech and AI at October Conferences
Protai, the Israel-based structural proteomics and AI-focused biotechnology firm, has made significant strides in the biotech industry, illustrating its importance by participating in four important scientific conferences throughout October 2025. The company showcased its groundbreaking work in targeted protein degradation and AI-assisted drug discovery that promises to transform the landscape of pharmaceutical development.
On October 6-8, Protai's Head of Proteomics, Dr. Anjana Shenoy, delivered a compelling presentation at the 13th Symposium on Structural Proteomics. Her discussion centered on innovative findings regarding modeling the transient pocket of TNFα (Tumor Necrosis Factor alpha). By integrating AI-driven conformational models with mass-spectrometry-based structural proteomics, the research opens exciting therapeutic possibilities for modulating the TNF signaling pathway. This pathway is known to play a crucial role in several inflammatory and autoimmune disorders, suggesting a beneficial application for pharmaceutical treatment in these areas.
Later in the month, on October 22, at the MoML@MIT 2025 conference held in Cambridge, Massachusetts, Protai's CEO, Eran Seger, presented the capabilities of their AIMS™ platform. The AIMS™ platform creatively intersects AI technology with structural proteomics to unearth hidden, dynamic druggable pockets from complex proteins such as TNFα. The insights gained from this innovative technology enable the rational design of small-molecule therapeutics, overcoming challenges faced by traditional structure-based methods.
As the month progresses, on October 27-30, Protai will be taking part in the Targeted Protein Degradation (TPD) Induced Proximity Summit in Boston. The company’s Chief Technology Officer (CTO), Kirill Pevzner, is scheduled to share the latest developments surrounding targeted protein degradation, including an exciting new KAT6A degrader created through the AIMS™ platform. This degrader has promising implications for therapeutic strategies involving protein-protein interactions and the targeting of specific proteins within complex systems.
In addition to these key conferences, Protai will participate in the ACR Convergence 2025 event in Chicago, Illinois. This marks a significant step in the company's strategic expansion into the realm of Immunology and Inflammation (II), wherein the biotechnology sector has high demand for innovation and therapeutic solutions.
Eran Seger, reflecting on the company's mission, stated, "Our goal is to redefine how the industry approaches the discovery of PPI (Protein-Protein Interaction) inhibitors and therapeutics designed for induced proximity. By fusing experimental evidence driven by proteomics with next-generation AI modeling, we are revealing previously unseen opportunities that classical drug discovery models have overlooked."
Protai is recognized as a leader in structural proteomics and AI-driven biotechnological solutions, pioneering Proteomics-aware-AI for drug discovery. The AIMS™ (AI-Mass-Spectrometry) platform represents an integrative solution that combines mass-spectrometry-based structural proteomics with experimental validation and AI modeling to depict dynamic protein conformations. This advancement enables the discovery of novel drugs while spanning critical areas including oncology and immunology, which address significant unmet medical needs.
The potential impacts of Protai’s work are profound, offering new hope for effective treatments in diseases where therapeutic options are currently limited. As they continue to unveil the complexities of protein structures and dynamics, the biotechnology landscape may see revolutionary changes that enhance our approach to drug discovery and development.
On October 6-8, Protai's Head of Proteomics, Dr. Anjana Shenoy, delivered a compelling presentation at the 13th Symposium on Structural Proteomics. Her discussion centered on innovative findings regarding modeling the transient pocket of TNFα (Tumor Necrosis Factor alpha). By integrating AI-driven conformational models with mass-spectrometry-based structural proteomics, the research opens exciting therapeutic possibilities for modulating the TNF signaling pathway. This pathway is known to play a crucial role in several inflammatory and autoimmune disorders, suggesting a beneficial application for pharmaceutical treatment in these areas.
Later in the month, on October 22, at the MoML@MIT 2025 conference held in Cambridge, Massachusetts, Protai's CEO, Eran Seger, presented the capabilities of their AIMS™ platform. The AIMS™ platform creatively intersects AI technology with structural proteomics to unearth hidden, dynamic druggable pockets from complex proteins such as TNFα. The insights gained from this innovative technology enable the rational design of small-molecule therapeutics, overcoming challenges faced by traditional structure-based methods.
As the month progresses, on October 27-30, Protai will be taking part in the Targeted Protein Degradation (TPD) Induced Proximity Summit in Boston. The company’s Chief Technology Officer (CTO), Kirill Pevzner, is scheduled to share the latest developments surrounding targeted protein degradation, including an exciting new KAT6A degrader created through the AIMS™ platform. This degrader has promising implications for therapeutic strategies involving protein-protein interactions and the targeting of specific proteins within complex systems.
In addition to these key conferences, Protai will participate in the ACR Convergence 2025 event in Chicago, Illinois. This marks a significant step in the company's strategic expansion into the realm of Immunology and Inflammation (II), wherein the biotechnology sector has high demand for innovation and therapeutic solutions.
Eran Seger, reflecting on the company's mission, stated, "Our goal is to redefine how the industry approaches the discovery of PPI (Protein-Protein Interaction) inhibitors and therapeutics designed for induced proximity. By fusing experimental evidence driven by proteomics with next-generation AI modeling, we are revealing previously unseen opportunities that classical drug discovery models have overlooked."
Protai is recognized as a leader in structural proteomics and AI-driven biotechnological solutions, pioneering Proteomics-aware-AI for drug discovery. The AIMS™ (AI-Mass-Spectrometry) platform represents an integrative solution that combines mass-spectrometry-based structural proteomics with experimental validation and AI modeling to depict dynamic protein conformations. This advancement enables the discovery of novel drugs while spanning critical areas including oncology and immunology, which address significant unmet medical needs.
The potential impacts of Protai’s work are profound, offering new hope for effective treatments in diseases where therapeutic options are currently limited. As they continue to unveil the complexities of protein structures and dynamics, the biotechnology landscape may see revolutionary changes that enhance our approach to drug discovery and development.
Topics Health）
【About Using Articles】
You can freely use the title and article content by linking to the page where the article is posted.
※ Images cannot be used.
【About Links】
Links are free to use.